Resources
20 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 8/11/2023 (updated 3/26/2024)
The Substance Abuse and Mental Health Services Administration (SAMHSA) has new resources available when supporting pregnant and parenting people with substance use disorders. Each resource supplements the SAMHSA Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication.
Posted 7/6/2022 (updated 3/27/2024)
Investment in rural maternal care is a featured priority of the new all-of-government approach to high rates of maternal mortality across the United States. The plan announced last week stresses more staff and capabilities for rural obstetrics and increased funding of the HRSA/FORHP-supported Rural Maternity and Obstetrics Management Strategies Program. A 2019 study from the Rural Health Research Gateway found a greater number of potentially life-threatening complications with childbirth in rural areas.
Posted 6/7/2022 (updated 3/27/2024)
Cohort-Specific Sessions/Activities and Day 2 Wrap-Up
Posted 5/17/2023 (updated 3/27/2024)
Illuminate Colorado, an RCORP Neonatal Abstinence Syndrome (NAS) grantee, and partners presented on their Tough as a Mother campaign. Tough as a Mother is a statewide campaign launched in May 2020 and has been working to decrease the stigma around maternal substance use disorder. The Illuminate Colorado Team provided an overview of their campaign and how others can access the shared resources, followed by time for Q&A.
Posted 12/21/2022 (updated 3/27/2024)
The Substance Abuse and Mental Health Services Administration released a notice of proposed rulemaking that would allow certified opioid treatment programs to begin prescribing the drug via audio-only or video-enabled telehealth. See additional information under Policy Updates below. The proposed changes come on top of recent findings by HHS of the positive impact of its revised Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder that removed two longstanding requirements for obtaining a waiver to treat up to 30 patients with buprenorphine: 1) the requirement for specific training, and 2) the need for otherwise eligible clinicians to certify their ability to provide or refer patients for counseling and other services. Rural primary care providers have obtained the DEA waiver at a lower rate than urban clinicians; decreased burden and greater flexibility in the guidelines, along with broader use of telehealth could help close that gap.
Posted 6/12/2020 (updated 3/28/2024)
Mother & Baby Substance Exposure Toolkit Best Practices All Best Practices came as a part of the California Medication Assisted Treatment Expansion Project
Posted 7/28/2021 (updated 4/2/2024)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.
Posted 9/1/2021 (updated 4/2/2024)
Posted 9/1/2021 (updated 4/2/2024)
Posted 9/1/2021 (updated 4/2/2024)
Affinity Group Breakout Sessions: Listed facilitators will briefly present and lead a group discussion on their respective topics.